Introduction
============

Venous thromboembolism (VTE), comprising deep venous thrombosis and pulmonary embolism, is a frequent disease with high morbidity and mortality, which affects 1--2 per 1,000 individuals ([@b1-mmr-12-05-7358]--[@b3-mmr-12-05-7358]). Furthermore, VTE is associated with a significant rate of recurrence in as many as 30% of VTE patients after termination of the standard course of anti-coagulant therapy ([@b4-mmr-12-05-7358]--[@b6-mmr-12-05-7358]). Therefore, it is desired to explore the molecular mechanisms and potential biomarkers that enable clinicians to identify patients at a risk of single VTE (SVTE) or recurrent VTE (RVTE) for prompt clinical diagnosis and early prevention ([@b7-mmr-12-05-7358]).

Kyrle *et al* ([@b8-mmr-12-05-7358]) reported that patients with a high level of factor VIII have an increased risk of RVTE. A study by Comp and Esmon ([@b9-mmr-12-05-7358]) suggested that the levels of protein S may be used in the evaluation of RVTE. Various established and novel biomarkers, including D-dimer, E-selectin, P-selectin, thrombin, inflammatory markers and C-reactive protein, have been investigated for their predictive value in SVTE and RVTE ([@b10-mmr-12-05-7358]--[@b13-mmr-12-05-7358]). However, only a small number of biomarkers, such as D-dimer, associated with a first or recurrent event of VTE were highlighted by these studies, while novel and promising biomarkers, including P-selectin and inflammatory cytokines, are still controversial ([@b1-mmr-12-05-7358]). A study by Lewis *et al* ([@b14-mmr-12-05-7358]) performed a pathway enrichment analysis of differentially expressed genes (DEGs) in samples from patients with SVTE and samples from patients with RVTE and found that insulin-like growth factor receptor 1 and Akt pathways may be useful for distinguishing patients with SVTE from those with RVTE.

The present study identified DEGs in RVTE and SVTE, as well as specific DEGs in RVTE. Functional and pathway enrichment analyses for these DEGs were performed to explore the molecular mechanisms and potential biomarkers of SVTE and RVTE in order to facilitate the diagnosis and clinical therapy management of VTE.

Materials and methods
=====================

Affymetrix microarray data
--------------------------

The gene expression profile dataset GSE19151 was obtained from Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>), which was deposited by Lewis *et al* ([@b14-mmr-12-05-7358]). Microarray data from 133 whole blood specimens were available, including 63 samples from healthy controls, 32 samples from patients with SVTE (sampled at \<three years since their most recent VTE) and 38 samples from subjects with recurrent venous thromboembolism (RVTE) on warfarin. The platform was GPL571 (HG-U133A_2) Affymetrix Human Genome U133A 2.0 Array (Affymetrix, Inc., Santa Clara, CA, USA).

DEG analysis and gene clustering analysis
-----------------------------------------

For the GSE19151 dataset, the Bioconductor software package in R (<http://www.bioconductor.org/>; version 3.1) was implemented to analyze the 133 blood gene chips ([@b15-mmr-12-05-7358]). Background correction and quartile data normalization were performed using the robust multiarray average algorithm with defaulted parameters in the Affy package (<http://www.bioconductor.org/packages/release/bioc/html/affy.html>; version 1.46.1) ([@b16-mmr-12-05-7358]). The t-test was used to identify DEGs using the Simpleaffy package (<http://www.bioconductor.org/packages/release/bioc/html/simpleaffy.html>; version 2.44.0) ([@b17-mmr-12-05-7358]). The DEGs were selected with the cutoff criteria of P\<0.05 and \|log(fold change)\|\>1. Hierarchical clustering analysis of the DEGs was performed using the Hclust command in R and the default complete linkage method ([@b18-mmr-12-05-7358]).

Gene ontology (GO) functional and pathway enrichment analyses
-------------------------------------------------------------

The Integrated GEne and PROtein annotation Server (IGEPROS; <http://www.biosino.org/iGepros/index.jsp>) ([@b19-mmr-12-05-7358]) bioinformatics resources consist of an integrated biological knowledge base and analytic tools aimed at systematically extracting biological information from large gene or protein lists. IGEPROS was used to perform the GO (<http://www.geneontology.org/>) functional and Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/pathway.html>) pathway enrichment analyses for the identified DEGs with the threshold of P\<0.05. The pathview package in R was utilized to depict the KEGG pathway ([@b20-mmr-12-05-7358]).

Results
=======

DEG selection and hierarchical clustering analysis
--------------------------------------------------

A total of 42 DEGs were identified between RVTE and normal whole-blood specimens (RVTE vs. control), including 35 up- and 7 downregulated genes. Subsequently, 20 DEGs between SVTE and normal whole-blood specimens (SVTE vs. control) were identified, including 17 up- and 3 downregulated genes. A total of 22 non-overlapping genes were selected as specific DEGs of RVTE, including 18 up- and 4 downregulated genes ([Table I](#tI-mmr-12-05-7358){ref-type="table"}). Hierarchical clustering analysis was performed for the 42 DEGs from the 133 whole blood specimens of patients with SVTE, patients with RVTE and healthy controls. The result of this clustering analysis suggested that these DEGs may have important roles in VTE ([Fig. 1](#f1-mmr-12-05-7358){ref-type="fig"}).

GO enrichment analysis of DEGs
------------------------------

GO enrichment analysis was performed for 42 DEGs in RVTE, 20 DEGs in SVTE and 22 specific DEGs of RVTE. In RVTE, most enriched GO terms of DEGs in biological processes were associated with biopolymer biosynthesis, including cellular protein metabolism (P=1.12×10^−8^), gene expression (P=1.36×10^−6^), translational elongation (P=9.65×10^−27^) and cellular macromolecular biosynthetic processes (P=8.78×10^−6^). In the cellular component category, enriched GO terms were mainly associated with the ribosomal sub-unit (P=2.03×10^−18^), cytosol (P=2.43×10^−12^) and macromolecular complexes (P=8.61×10^−11^). In the molecular function category, GO terms enriched for DEGs in RVTE included structural constituents of ribosomes (P=9.13×10^−24^), insulin-like growth factor binding (P=0.002) and beta-adrenergic receptor kinase activity (P=0.005) ([Tables II](#tII-mmr-12-05-7358){ref-type="table"}--[IV](#tIV-mmr-12-05-7358){ref-type="table"}).

In SVTE, the most significantly enriched GO terms for DEGs in biological processes included biopolymer biosynthesis (P=2.35×10^−5^), translational elongation (P=2.35×10^−5^), cellular protein metabolism (P=1.24×10^−7^) and rRNA processing (P=0.006). The predominantly enriched GO terms of the cellular component category were the cytosol (P=1.68×10^−11^), the cytosolic large ribosomal sub-unit (P=8.62×10^−10^) and macromolecular complexes (P=4.86×10^−9^). The main GO terms of DEGs in SVTE in the molecular function category were structural constituents of ribosomes (P=4.69×10^−20^), RNA binding (P=2.79×10^−5^) and protein channel activity (P=0.001). Among the DEGs in SVTE, 12 genes, including RPS3A and RPS7, were involved in translational elongation, 2 genes (UQCRQ and COX7C) were involved in oxidoreductase activity and 2 genes (HINT1 and LAMP1) were associated with proteolysis ([Tables II](#tII-mmr-12-05-7358){ref-type="table"}--[IV](#tIV-mmr-12-05-7358){ref-type="table"}).

The GO terms for biological processes of the 22 specific DEGs of RVTE were mainly translational elongation (P=3.52×10^−7^), negative regulation of the force of heart contraction by chemical signals (P=0.001) and cell proliferation (P=0.002). In the cellular component category, enriched GO terms were mainly associated with the cytosolic small ribosomal sub-unit (P=1.56×10^−5^), ribosomal sub-unit (P=1.84×10^−5^) and macromolecular complexes (P=0.0008). The specific GO terms of the 22 specific DEGs in RVTE in the molecular function category were mainly associated with structural constituents of ribosomes (P=2.55×10^−6^), insulin-like growth factor binding (P=0.0006), beta-adrenergic receptor kinase activity (P=0.003) and phospholipase A2 inhibitor activity (P=0.004). Two genes (IGF2R and IGFBP7) were shown to be involved in anti-apoptotic signaling, ten genes, including RPL21 and RPS21, were involved in translational elongation and six genes, including NDUFA5, ATP5O and ADRBK1, were associated with the force of heart contraction ([Tables II](#tII-mmr-12-05-7358){ref-type="table"}--[IV](#tIV-mmr-12-05-7358){ref-type="table"}).

Pathway enrichment analysis of DEGs
-----------------------------------

The DEGs identified in the present study were enriched in nine pathways ([Table V](#tV-mmr-12-05-7358){ref-type="table"}). The RVTE DEGs were mainly enriched in ribosomal pathways (P=1.59×10^−23^), Parkinson\'s disease (P=0.007) and oxidative phosphorylation (P=0.008). The SVTE DEGs were enriched in ribosomal pathways (P=4.58×10^−19^) and cardiac muscle contraction (P=0.025). The non-overlapping DEGs were enriched in ribosomal pathways (P=2.25×10^−6^) and protein export (P=0.03).

Metabolic pathway visualization analysis of specific DEGs of RVTE
-----------------------------------------------------------------

The metabolic pathways were visualized in schemes depicting the ribosomal pathway ([Fig. 2](#f2-mmr-12-05-7358){ref-type="fig"}) and the protein export pathway ([Fig. 3](#f3-mmr-12-05-7358){ref-type="fig"}; <http://www.genome.jp/kegg/tool/map_pathway2.html>). In the ribosomal pathway, RPL21, RPS21, RPS24 and RPS27 were upregulated and in the protein export pathway, SRP9 was upregulated. The results suggested that these genes may be critical in RVTE and that certain variations in the expression of these genes may lead to an increased risk of recurrence.

Discussion
==========

In recent years, the application of adequate thromboprophylaxis has led to significant progress in the management of VTE by successfully reducing morbidity and mortality ([@b21-mmr-12-05-7358]). However, to date, methods for effectively preventing and diagnosing SVTE and RVTE have remained controversial ([@b22-mmr-12-05-7358]). The present study used bioinformatics methods to investigate the molecular mechanisms and potential biomarkers of SVTE and RVTE.

In the present study, gene expression profiles of whole blood samples were successfully used to screen for DEGs in specimens from patients with SVTE compared with those in control specimens. With regard to enriched biological processes and pathways for DEGs in SVTE, genes involved in ribosomal pathways, including RPS3A and RPS7, and mitochondrial function, including UQCRQ and COX7C, were indicated to be most consistently affected and modulated. Ribosomal proteins have remained highly conserved during evolution and reflect critical functions in ribosome biogenesis; in addition, several ribosomal proteins were shown to have extra-ribosomal functions in apoptosis, DNA repair and genetic disease ([@b23-mmr-12-05-7358]). A total of 12 DEGs were involved in ribosomal pathways. A paucity of studies have explored the pathogenesis of VTE. It has previously been indicated that the ribosomal-related RP-MDM2-P53 axis may be involved in the molecular pathogenesis of the 5q syndrome, and VTE was reported in 3% of patients with 5q syndrome ([@b24-mmr-12-05-7358]). COX7C and UQCRQ are constituents of the mitochondrial respiratory chain ([@b25-mmr-12-05-7358]). Mutations of these two genes may increase oxidative stress in coronary artery disease ([@b26-mmr-12-05-7358]). The mortality after VTE is strongly associated with presentation of underlying cardiovascular disease ([@b27-mmr-12-05-7358]). First-time VTE in numerous patients is idiopathic and challenging to diagnose, while COX7C and UQCRQ may represent novel biomarkers to identify SVTE.

The specific DEGs in RVTE were found to be mainly involved in ribosomal pathways, heart contraction and oxidative phosphorylation. Pathway visualization revealed that RPL21, RPS21, RPS24 and RPS27, which all encode ribosomal proteins, were enriched in ribosomal pathways, while SRP9 was enriched in the protein export pathway. Furthermore, RPL21, RPS21, RPS24 and RPS27 were found to be involved in RVTE through critical ribosome biogenesis or extra-ribosomal functions; of note, the expression of these genes was upregulated in patients with RVTE but unchanged in patients with SVTE. It has been reported that certain diseases, including transient ischemia/reperfusion and preeclampsia, are associated with ribosomes ([@b28-mmr-12-05-7358],[@b29-mmr-12-05-7358]). RPS24 mutation was potentially linked to pathologies of Diamond-Blackfan anemia ([@b30-mmr-12-05-7358]). The above results suggested that RPL21, RPS21, RPS24 and RPS27 may have critical roles in RVTE.

The results of the present study showed that β-adrenergic receptor kinase 1 (ADRBK1) was closely associated with RVTE and involved in heart contraction. Polymorphisms in ADRB2 and LPL genes are known to have central roles in vascular biology ([@b31-mmr-12-05-7358]). A previous study suggested that the use of ADRBK1 as a biomarker significantly improved heart failure therapy ([@b32-mmr-12-05-7358]). Certain studies showed that the ADRBK1/phosphoinositide-3 kinase (PI3K) complex improved cardiac function and that PI3K-dependent phosphorylation of ADRBK1 on Ser670 is responsible for the downregulation of ADRBK1 protein via a proteasome-dependent pathway ([@b33-mmr-12-05-7358],[@b34-mmr-12-05-7358]). Furthermore, PI3K influences insulin-like growth factor and blood vessel-related factor through G protein beta gamma ([@b35-mmr-12-05-7358]). These results may suggest that ADRBK1 has a critical role in RVTE by serving as a dual effector of the compensatory myocardial diastole and the PI3K response.

The present study also identified NDUFA5 and ATP ATP5O as DEGs, which were significantly associated with oxidative phosphorylation. The oxidative stress injury and exitotoxicity in mitochondria induced by NDUFA5 and ATP5O have been proved to be the cause of a variety of nervous system degenerative diseases, including Parkinson\'s, Alzheimer\'s and Huntington\'s disease ([@b36-mmr-12-05-7358],[@b37-mmr-12-05-7358]). Free-radical generation and consequent oxidative stress in platelet activation and thrombotic vascular diseases have a distinctive role with the potential injurious effects of homocysteine ([@b38-mmr-12-05-7358],[@b39-mmr-12-05-7358]). Therefore, NDUFA5 and ATP5O inducing oxidative stress injury and exitotoxicity in mitochondria may also have an impact on RVTE.

In conclusion, the screening performed in the present study identified 42 DEGs in RVTE, including 35 up- and 7 downregulated genes, 20 DEGs in SVTE, including 17 up- and 3 downregulated genes, and 22 specific DEGs in RVTE. Furthermore, functional and pathway enrichment analysis was performed for these identified DEGs. The results indicated that DEGs in SVTE, including COX7C and UQCRQ, may be used as potential biomarkers for SVTE and that specific DEGs in RVTE, including ADRBK1, NDUFA5 and ATP5O, may be considered as potential biomarkers of RVTE. However, experimental studies are required to confirm these results.
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###### 

Specific differentially expressed genes of recurrent VTE.

  Probe ID       Mean of recurrent VTE (R)   Mean of healthy (N)   Log2 (R/N)   P-value        Gene symbol   ENTREZGENE_ID
  -------------- --------------------------- --------------------- ------------ -------------- ------------- ---------------
  201304_at      6.22                        4.64                  1.58         2.55×10^−5^    NDUFA5        4698
  200679_x\_at   9.86                        8.67                  1.19         4.85×10^−10^   HMGB1         3146
  201317_s\_at   9.49                        8.16                  1.33         2.18×10^−7^    PSMA2         5683
  200977_s\_at   9.41                        8.16                  1.24         1.39×10^−5^    TAX1BP1       8887
  201152_s\_at   11.86                       10.69                 1.17         1.17×10^−6^    MBNL1         4154
  201163_s\_at   8.79                        7.54                  1.24         1.19×10^−12^   IGFBP7        3490
  201593_s\_at   9.38                        8.26                  1.12         3.27×10^−10^   ZC3H15        55854
  201401_s\_at   8.57                        9.69                  −1.13        1.39×10^−11^   ADRBK1        156
  200834_s\_at   12.54                       11.54                 1.01         1.97×10^−11^   RPS21         6227
  201367_s\_at   8.91                        10.14                 −1.24        2.12×10^−7^    ZFP36L2       678
  201392_s\_at   9.09                        10.22                 −1.13        5.39×10^−10^   IGF2R         3482
  201200_at      10.98                       9.82                  1.16         1.72×10^−11^   CREG1         8804
  200012_x\_at   13.08                       11.66                 1.42         1.40×10^−6^    RPL21         6144
  200061_s\_at   11.34                       9.94                  1.40         4.02×10^−9^    RPS24         6229
  200741_s\_at   13.56                       12.34                 1.22         1.28×10^−11^   RPS27         6232
  200880_at      8.92                        7.73                  1.19         1.17×10^−7^    DNAJA1        3301
  201012_at      10.84                       9.29                  1.55         2.33×10^−9^    ANXA1         301
  201273_s\_at   10.76                       9.69                  1.07         0.000332       SRP9          6726
  201332_s\_at   8.22                        9.35                  −1.13        1.44×10^−13^   STAT6         6778
  201406_at      10.35                       9.03                  1.32         6.59×10^−5^    RPL36A        6173
  201023_at      9.93                        8.76                  1.17         0.000185       TAF7          6879
  200818_at      10.17                       9.16                  1.02         5.51×10^−5^    ATP5O         539

VTE, venous thromboembolism; R, recurrent; N, normal.

###### 

GO functional enrichment analysis of DEGs in patients with RVTE and SVTE, and top 10 specific DEGs of RVTE associated with biological processes.

  Category/GOBPID   P-value        Count (n)   Size (n)   Term
  ----------------- -------------- ----------- ---------- --------------------------------------------------------------------------
  RVTE                                                    
   GO:0006414       9.65×10^−27^   17          104        Translational elongation
   GO:0044267       1.12×10^−8^    22          2361       Cellular protein metabolic process
   GO:0010467       1.36×10^−6^    25          3592       Gene expression
   GO:0043284       2.88×10^−6^    23          3183       Biopolymer biosynthetic process
   GO:0034645       8.78×10^−6^    23          3386       Cellular macromolecule biosynthetic process
   GO:0044237       1.49×10^−5^    34          7160       Cellular metabolic process
   GO:0009058       0.000114       24          4223       Biosynthetic process
   GO:0042274       0.000360       2           10         Ribosomal small subunit biogenesis
   GO:0044238       0.001536       31          7368       Primary metabolic process
   GO:0006364       0.002059       3           88         rRNA processing
  SVTE                                                    
   GO:0006414       7.47×10^−22^   12          106        Translational elongation
   GO:0044267       1.24×10^−7^    14          2499       Cellular protein metabolic process
   GO:0043284       2.35×10^−5^    13          3183       Biopolymer biosynthetic process
   GO:0034645       4.76×10^−5^    13          3386       Cellular macromolecule biosynthetic process
   GO:0010467       9.42×10^−5^    11          3052       Gene expression
   GO:0044237       0.000402       17          7160       Cellular metabolic process
   GO:0009058       0.000549       13          4223       Biosynthetic process
   GO:0006610       0.004003       1           3          Ribosomal protein import into nucleus
   GO:0006364       0.006046       2           88         rRNA processing
   GO:0042273       0.010641       1           8          Ribosomal large subunit biogenesis
  Non-overlap                                             
   GO:0006414       3.52×10^−7^    5           104        Translational elongation
   GO:0000296       0.001547       1           1          Spermine transport
   GO:0003108       0.001547       1           1          Negative regulation of the force of heart contraction by chemical signal
   GO:0008283       0.002157       6           917        Cell proliferation
   GO:0044267       0.002941       9           2361       Cellular protein metabolic process
   GO:0006916       0.002998       3           190        Anti-apoptosis
   GO:0048523       0.003033       7           1334       Negative regulation of cellular process
   GO:0045988       0.003092       1           2          Negative regulation of striated muscle contraction
   GO:0045900       0.003092       1           2          Negative regulation of translational elongation
   GO:0048295       0.003092       1           2          Positive regulation of isotype switching to IgE isotypes

GO, gene ontology; DEG, differentially expressed genes; RVTE, recurrent venous thromboembolism; SVTE, single venous thromboembolism; non-overlap, non-overlapping DEGs as specific DEGs of RVTE; GOBPID, gene ontology biological process identification number; IgE, immunoglobulin E; Count, DEG numbers enriched in the specific GO term; Size, total gene numbers in the GO database.

###### 

GO functional enrichment analysis of DEGs in patients with RVTE and SVTE, and top 10 specific DEGs of RVTE associated with cellular components.

  Category/GOCCID   P-value        Count (n)   Size (n)   Term
  ----------------- -------------- ----------- ---------- ----------------------------------------------------
  RVTE                                                    
   GO:0033279       2.03×10^−18^   13          118        Ribosomal sub-unit
   GO:0005829       2.43×10^−12^   19          1039       Cytosol
   GO:0032991       8.61×10^−11^   25          2482       Macromolecular complex
   GO:0022627       4.11×10^−10^   6           36         Cytosolic small ribosomal sub-unit
   GO:0022625       5.80×10^−10^   6           38         Cytosolic large ribosomal sub-unit
   GO:0043228       2.18×10^−9^    23          2388       Non-membrane-bound organelle
   GO:0005737       1.12×10^−7^    35          6946       Cytoplasm
   GO:0005840       1.16×10^−5^    4           78         Ribosome
   GO:0005622       5.89×10^−5^    39          10646      Intracellular
   GO:0005730       0.001773       7           680        Nucleolus
  SVTE                                                    
   GO:0005829       1.68×10^−11^   13          1039       Cytosol
   GO:0022625       8.62×10^−10^   5           38         Cytosolic large ribosomal sub-unit
   GO:0032991       4.86×10^−9^    15          2482       Macromolecular complex
   GO:0043228       4.10×10^−8^    14          2388       Non-membrane-bound organelle
   GO:0044422       2.04×10^−6^    15          3829       Organelle part
   GO:0022627       1.16×10^−5^    3           36         Cytosolic small ribosomal sub-unit
   GO:0033279       1.53×10^−5^    3           57         Ribosomal sub-unit
   GO:0005840       1.82×10^−5^    3           78         Ribosome
   GO:0043229       7.82×10^−5^    19          8645       Intracellular organelle
   GO:0005622       0.000279       20          10646      Intracellular
  Non-overlap                                             
   GO:0022627       1.56×10^−5^    3           36         Cytosolic small ribosomal sub-unit
   GO:0033279       1.84×10^−5^    4           118        Ribosomal sub-unit
   GO:0032991       0.000837       10          2482       Macromolecular complex
   GO:0005737       0.001286       17          6946       Cytoplasm
   GO:0008024       0.001373       1           1          Positive transcription elongation factor complex b
   GO:0005829       0.002221       6           1039       Cytosol
   GO:0005785       0.002744       1           2          Signal recognition particle receptor complex
   GO:0043232       0.002811       9           2388       Intracellular non-membrane-bound organelle
   GO:0005641       0.006847       1           5          Nuclear envelope lumen
   GO:0044422       0.006937       11          3829       Organelle part

GO, gene ontology; DEG, differentially expressed genes; RVTE, recurrent venous thromboembolism; SVTE, single venous thromboembolism; Non-overlap, non-overlapping DEGs as specific DEGs of RVTE; GOCCID, gene ontology cellular component identification number; Count, DEG numbers enriched in the specific GO term; Size, total gene numbers in the GO database.

###### 

GO functional enrichment analysis of DEGs in patients with RVTE and SVTE, and top 10 specific DEGs of RVTE associated with molecular function.

  Category/GOMFID   P-value        Count (n)   Size (n)   Term
  ----------------- -------------- ----------- ---------- ----------------------------------------------------------------------------------
  RVTE                                                    
   GO:0003735       9.13×10^−24^   17          158        Structural constituent of ribosome
   GO:0003723       2.87×10^−6^    10          646        RNA binding
   GO:0005520       0.002031       2           25         Insulin-like growth factor binding
   GO:0015266       0.002686       1           1          Protein channel activity
   GO:0015077       0.002942       3           107        Monovalent inorganic cation transmembrane transporter activity
   GO:0047696       0.005365       1           2          Beta-adrenergic receptor kinase activity
   GO:0005010       0.008037       1           3          Insulin-like growth factor receptor activity
   GO:0019834       0.008037       1           3          Phospholipase A2 inhibitor activity
   GO:0003729       0.008574       2           52         mRNA binding
   GO:0005047       0.010702       1           4          Signal recognition particle binding
  SVTE                                                    
   GO:0003735       4.69×10^−20^   12          158        Structural constituent of ribosome
   GO:0003723       2.79×10^−5^    6           630        RNA binding
   GO:0015266       0.001245       1           1          Protein channel activity
   GO:0003729       0.001876       2           52         mRNA binding
   GO:0015077       0.007702       2           107        Monovalent inorganic cation transmembrane transporter activity
   GO:0008121       0.009917       1           8          Ubiquinol-cytochrome C reductase activity
   GO:0016679       0.009917       1           8          Oxidoreductase activity, acting on diphenols and associated substances as donors
   GO:0030552       0.017294       1           14         cAMP binding
   GO:0005080       0.018518       1           15         Protein kinase C binding
   GO:0008603       0.019741       1           16         cAMP-dependent protein kinase regulator activity
  Non-overlap                                             
   GO:0003735       2.55×10^−6^    5           158        Structural constituent of ribosome
   GO:0005520       0.000583       2           25         Insulin-like growth factor binding
   GO:0047696       0.002881       1           2          Beta-adrenergic receptor kinase activity
   GO:0005010       0.004318       1           3          Insulin-like growth factor receptor activity
   GO:0019834       0.004318       1           3          Phospholipase A2 inhibitor activity
   GO:0005047       0.005753       1           4          Signal recognition particle binding
   GO:0035035       0.008618       1           6          Histone acetyltransferase binding
   GO:0008312       0.008618       1           6          7S RNA binding
   GO:0004703       0.010048       1           7          G-protein coupled receptor kinase activity
   GO:0031369       0.011475       1           8          Translation initiation factor binding

GO, gene ontology; DEG, differentially expressed genes; RVTE, recurrent venous thromboembolism; SVTE, single venous thromboembolism; Non-overlap, non-overlapping DEGs as specific DEGs of RVTE; cAMP, cyclic adenosine monophosphate; GOMFID, gene ontology molecular function identification number ; Count, DEG numbers enriched in the specific GO term; Size, total gene numbers in the GO database.

###### 

KEGG pathway enrichment analysis of DEGs in patients with RVTE and SVTE, and specific DEGs of RVTE.

  Category/KEGGID   P-value        Count (n)   Size (n)   Term
  ----------------- -------------- ----------- ---------- ----------------------------
  RVTE                                                    
   K03010           1.59×10^−23^   17          86         Ribosome
   K05012           0.007377       4           133        Parkinson\'s disease
   K00190           0.007772       4           135        Oxidative phosphorylation
   K05010           0.017421       4           171        Alzheimer\'s disease
   K05016           0.022594       4           185        Huntington\'s disease
  SVTE                                                    
   K03010           4.58×10^−19^   12          86         Ribosome
   K04260           0.025106       2           79         Cardiac muscle contraction
  Non-overlap                                             
   K03010           2.25×10^−6^    5           86         Ribosome
   K03060           0.03007        1           11         Protein export

KEGG, Kyoto Encyclopedia of Genes and Genomes; DEG, differentially expressed genes; RVTE, recurrent venous thromboembolism; SVTE, single venous thromboembolism; Non-overlap, non-overlapping DEGs as specific DEGs of RVTE. KEGGID, KEGG identification number. Count, number of DEGs enriched in the specific GO term; size, number of genes in the GO database.
